Asad Haider
Stock Analyst at Goldman Sachs
(4.78)
# 573
Out of 5,124 analysts
146
Total ratings
84.4%
Success rate
26.7%
Average return
Main Sectors:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintained: Buy | $127 | $90.70 | +40.02% | 9 | Nov 5, 2026 | |
| PFE Pfizer | Reiterated: Hold | $26 → $28 | $30.79 | -9.06% | 21 | Nov 4, 2026 | |
| ABBV AbbVie | Reiterated: Hold | $294 → $313 | $294.83 | +6.16% | 10 | Nov 2, 2026 | |
| LLY Eli Lilly and Company | Rated: Buy | $1,413 → $1,573 | $1,417.99 | +10.93% | 27 | Oct 30, 2026 | |
| JNJ Johnson & Johnson | Reiterated: Buy | $282 → $280 | $276.32 | +1.33% | 25 | Oct 26, 2026 | |
| MRK Merck & Co. | Reiterated: Buy | $155 | $150.36 | +3.09% | 24 | Oct 22, 2026 | |
| TYO: 4519 Chugai Pharmaceutical Co., Ltd. | Reiterated: Buy | ¥8,750 | ¥7,347 | +19.10% | 1 | Oct 20, 2026 | |
| BMY Bristol-Myers Squibb Company | Rated: Hold | $63 | $64.19 | -1.85% | 13 | Oct 19, 2026 | |
| PCVX Vaxcyte | Reiterated: Hold | $67 → $85 | $65.68 | +29.42% | 3 | Oct 6, 2026 | |
| RPRX Royalty Pharma | Reiterated: Buy | $59 → $66 | $67.56 | -2.31% | 4 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $37 → $38 | $20.93 | +81.56% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $17 → $18 | $21.26 | -15.33% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $270 | $478.48 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $66 | $10.65 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $168 | $203.11 | n/a | 1 | Dec 14, 2018 |
BioNTech SE
Nov 5, 2026
Maintained: Buy
Price Target: $127
Current: $90.70
Upside: +40.02%
Pfizer
Nov 4, 2026
Reiterated: Hold
Price Target: $26 → $28
Current: $30.79
Upside: -9.06%
AbbVie
Nov 2, 2026
Reiterated: Hold
Price Target: $294 → $313
Current: $294.83
Upside: +6.16%
Eli Lilly and Company
Oct 30, 2026
Rated: Buy
Price Target: $1,413 → $1,573
Current: $1,417.99
Upside: +10.93%
Johnson & Johnson
Oct 26, 2026
Reiterated: Buy
Price Target: $282 → $280
Current: $276.32
Upside: +1.33%
Merck & Co.
Oct 22, 2026
Reiterated: Buy
Price Target: $155
Current: $150.36
Upside: +3.09%
Chugai Pharmaceutical Co., Ltd.
Oct 20, 2026
Reiterated: Buy
Price Target: ¥8,750
Current: ¥7,347
Upside: +19.10%
Bristol-Myers Squibb Company
Oct 19, 2026
Rated: Hold
Price Target: $63
Current: $64.19
Upside: -1.85%
Vaxcyte
Oct 6, 2026
Reiterated: Hold
Price Target: $67 → $85
Current: $65.68
Upside: +29.42%
Royalty Pharma
Aug 6, 2026
Reiterated: Buy
Price Target: $59 → $66
Current: $67.56
Upside: -2.31%
May 7, 2026
Reiterated: Hold
Price Target: $37 → $38
Current: $20.93
Upside: +81.56%
May 6, 2026
Reiterated: Sell
Price Target: $17 → $18
Current: $21.26
Upside: -15.33%
Dec 16, 2019
Upgraded: Buy
Price Target: $270
Current: $478.48
Upside: n/a
Dec 16, 2019
Upgraded: Buy
Price Target: $66
Current: $10.65
Upside: n/a
Dec 14, 2018
Reiterated: Buy
Price Target: $168
Current: $203.11
Upside: n/a